Table 1 Demographic and baseline characteristics
Characteristic | LM25 (N = 80) | IGL (N = 82) | Total (N = 162) |
|---|---|---|---|
Country, n (%) | |||
Argentina | 40 (50.0) | 39 (47.6) | 79 (48.8) |
Brazil | 20 (25.0) | 23 (28.0) | 43 (26.5) |
Mexico | 20 (25.0) | 20 (24.4) | 40 (24.7) |
Sex, n (%) | |||
Male | 39 (48.8) | 30 (36.6) | 69 (42.6) |
Female | 41 (51.3) | 52 (63.4) | 93 (57.4) |
Age (years), mean (SD) | 57.5 (9.7) | 57.1 (8.4) | 57.3 (9.0) |
Weight (kg), mean (SD) | 82.5 (15.4 | 81.8 (15.0) | 82.2 (15.1) |
BMI (kg/m2), mean (SD) | 30.9 (4.8) | 31.7 (5.5) | 31.3 (5.2) |
Duration of diabetes (years), mean (SD) | 13.8 (7.9) | 12.9 (6.8) | 13.4 (7.3) |
HbA1c at screening | |||
%, mean (SD) | 8.8 (0.8) | 8.6 (0.8) | 8.7 (0.8) |
<8.5 %, n (%) | 33 (41.3) | 35 (42.7) | 68 (42.0) |
FPG (mg/dL), mean (SD) | 107.1 (37.1) | 98.5 (28.2) | 102.8 (33.0) |
Insulin glargine dose at screening (IU), mean (SD) | 39.3 (19.3) | 39.5 (18.9) | 39.4 (19.0) |
Glycemic variability (mg/dL), mean (SD) | 46.6 (18.8) | 49.7 (18.6) | 48.2 (18.7) |
Concomitant oral antidiabetic drugs | |||
Metformin, n (%) | 80 (100) | 82 (100) | 162 (100) |
Daily dose (mg), mean (SD) | 1968.1 (393.0) | 2062.8 (396.8) | 2016.0 (396.6) |
Pioglitazone, n (%) | 4 (5.0) | 5 (6.1) | 9 (5.6) |
Daily dose (mg), mean (SD) | 30.0 (0.0) | 30.0 (0.0) | 30.0 (0.0) |
Metformin and pioglitazone, n (%) | 4 (5.0) | 5 (6.1) | 9 (5.6) |